Background: Interaction of antiretrovirals with drug transporters such as P-glycoprotein (P-gp), multidrug resistance-associated protein (MRP), breast cancer resistance protein (BCRP) and solute carrier organic anion transporter (SLCO) may influence the emergence of viral mutants by altering intracellular drug concentrations. Here we characterize the effect of transporter expression in a variety of cell types such as control CEM, CEM VBL (P-gp-overexpressing), CEM E1000 (MRP1-overexpressing), MT4, control MDCKII, MDCKII MDR1 (P-gp-overexpressing) and peripheral blood mononuclear cells ( 
Introduction
Drug transporters act as a barrier to drug absorption, distribution, metabolism and excretion. Drug efflux pumps including P-glycoprotein (P-gp) and multidrug resistance-associated proteins 1 and 2 (MRP1, MRP2), influx pumps such as organic anion transporting polypeptides/solute carrier organic anion transporters (OATPs/SLCOs) and solute carrier (SLC) transport proteins transport antiretrovirals from several cellular compartments. 1 -3 Clearly drug efflux by transporters expressed at sites such as the blood -brain and blood -testis barriers and lymphocytes may decrease drug penetration into these organs, limiting the efficacy of substrate drugs and thereby allowing the evolution of viral mutants.
Given the potential relevance of drug transporters to the disposition of antiretrovirals, an increased understanding of how transporters may impact viral suppression is essential for optimizing therapy. Data on the interaction of the non-nucleoside reverse transcriptase inhibitors such as efavirenz and nevirapine with drug transporter proteins are conflicting.
The central focus of the current study is to investigate the expression and role of drug efflux transporters (e.g. P-gp and MRPs) and influx transporters (SLCOs) on the accumulation of [ 14 
Isolation of peripheral blood mononuclear cells (PBMCs)
Blood buffy coat samples from healthy volunteers (n¼ 5) were obtained from the blood transfusion service (Manchester, UK) from which PBMCs were isolated using lymphoprep following the manufacturer's instructions.
Ethics
No ethical approval was required in the collection and use of the blood products from the blood transfusion services.
Isolation of RNA
Total RNA was extracted from the cells (1Â10 7 ; PBMCs, CEM, CEM VBL , CEM E1000 , MT4 and A549) and reverse transcribed to cDNA as described previously. 3 
PCR analyses
Expression of mRNA for MDR1, MRP1, MRP2 and SLCOs was assessed by real-time RT-PCR using primers and probes obtained through the Applied Biosystems (New Jersey, USA) Assays-on-Demand range (http://www.appliedbiosystems.com). PCR primer sequences, incubation conditions and analysis were as described previously. 3 Octanol/saline partition coefficient 6 cells/mL for PBMCs) in the absence and presence of fixed concentrations of inhibitors: XR9576 (P-gp inhibitor; 0.01 -1 mM), MK571 (MRP inhibitor; 1-100 mM), GF120918 (P-gp inhibitor; 50 mM), dipyridamole (P-gp/MRP1 inhibitor; 50 mM) and influx inhibitors montelukast (10 -100 mM) and estrone-3-sulphate (1-100 mM) as described previously. 
Statistical analysis
Data are expressed as means+SD. The Shapiro-Wilk test was used to assess the distribution of the data. Statistically significant differences between controls and test samples were then assessed by paired t-test. Significance between controls and test samples was assumed if P,0.05.
Results

Expression of drug transporters
We have previously shown that CEM cells, CEM VBL cells, CEM E1000 cells and PBMCs express different OATP/SLCO transcripts.
3 MT4 cells showed transcripts of SLCO2B1, SLCO3A1 and SLCO4A1, as well as MRP1 and MRP2. As expected, MRP1 and MDR1 transcripts were detected in CEM E1000 and CEM VBL cells; however, no MDR1 transcript was detected in MT4 cells (data not shown). Figure 1a ). MK571 (50 mM) had no effect on the accumulation of 
Octanol/saline partition coefficient
Apical and basolateral transport of [ 3 H]nevirapine is independent of P-gp
We observed no differential apical or basal transport of [ 3 H]nevirapine in the MDCKII CTL and MDCKII MDR1 cells, with XR9576 (at 1 mM) having no effect on transport (Figure 2g) . In a similar experiment, using [ 3 H]saquinavir as a control, we observed that inhibition of P-gp with XR9576 (1 mM) significantly altered the transepithelial transport of [ 
Discussion
The ability of antiretroviral agents to target infected cells may be influenced by the chemistry of the drug, drug-metabolizing enzymes, drug transporters and other factors.
Here, we screened CEM cells, MT4 cells and PBMCs for expression of SLCO1A2, 1B1, 2B1, 3A1, 4A1 and 1B3 transcripts by RT-PCR and obtained the same results as those previously published.
3 MT4 cells expressed SLCO2B1, SLCO3A1 and 4A1. Both the CEM and MT4 cell line models differed from PBMCs in their expression profiles; the latter were found to express only SLCO3A1. 3, 11 A surprising finding in the present study was the lack of transcript for MDR1 in MT4 cells. This cell line is frequently used to assess antiviral activity via virally induced cytopathic effects, demonstrating that to be able to formulate a robust explanation of the mechanistic basis of the intracellular accumulation and activity of substrate drugs one needs an adequate understanding of the transporter profiles of the cells being used. (Figures 1 and 2 ). Our measured log D values for efavirenz are in agreement with previous studies (5.4 12 versus 5.1), but that for nevirapine was not (2.05 13 versus 1.2). This is probably because the value reported by Kasim et al. 13 was based on an estimated/calculated value rather than an experimental value.
We found no evidence that P-gp and MRP1 reduce the accumulation of [ Previous studies in Caco-2 cells, expressing a variety of transport proteins, and in GPNT cells provided some evidence that [
14 C]efavirenz is not a P-gp substrate. 2, 7 Additionally, we observed no correlation between P-gp expression and the intracellular concentration of efavirenz in PBMCs from HIV-infected subjects, 14 suggesting that the cellular accumulation of efavirenz may not be affected by P-gp or that multiple factors rather than a single protein control the entry and retention of a drug. However, prolonged exposure of LS180 V cells to efavirenz induced P-gp expression, 7 a finding supported in PBMCs by work from our laboratory. 4 The CAR of [ 14 C]efavirenz was decreased in each of the cell types by incubation with the OATP substrate and inhibitor estrone-3-sulphate, and montelukast, a known inhibitor of OATPs, 3, 15 suggesting that an SLCO-like uptake transporter ( possibly SLCO3A1) may be responsible for the accumulation of [ 14 C]efavirenz in these cells.
Our data suggest that [ 3 H]nevirapine is not a substrate of P-gp and MRP1/2, and this stems from three important direct observations: (i) there was no differential accumulation of 
